AP NEWS TEST SITE
Listen
ADVERTISEMENT
Press release content from News Direct Corporation. The AP news staff was not involved in its creation.
Related topics

Poolbeg Pharma identifies new RSV drug candidates

PRESS RELEASE: Paid content from News Direct Corporation
Press release content from News Direct Corporation. The AP news staff was not involved in its creation.
December 22, 2022 GMT
None
None

--News Direct--

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing that Poolbeg has identified several potential candidates from its Respiratory Syncytial Virus (RSV) AI collaboration with One Three Biotech. He also looks back on what the company achieved during 2022 and looks ahead to what investors can expect from Poolbeg in 2023.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View original content to download multimedia: https://newsdirect.com/news/poolbeg-pharma-identifies-new-rsv-drug-candidates-240574752

All contents © copyright 2023 The Associated Press. All rights reserved.